Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma
NCT02736266
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
174
Enrollment
OTHER
Sponsor class
Conditions
Urothelial Bladder Carcinoma
Interventions
DRUG:
Pembrolizumab (MK-3475)
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Collaborators
[object Object]